Updated Guide to Diagnosing and Treating Guillain-Barré Syndrome
A comprehensive review of immune-mediated polyneuropathies updates clinicians on GBS diagnosis, variants, and emerging targeted immunotherapies.
Summary
Guillain-Barré syndrome (GBS) is the most common cause of acute flaccid paralysis worldwide. This Spanish-language review from Hospital Sant Joan de Déu, Barcelona, covers the full spectrum of immune-mediated polyneuropathies, including the classic demyelinating form (AIDP) and axonal variants (AMAN, AMSAN), plus Miller-Fisher syndrome. Diagnosis relies on clinical assessment backed by cerebrospinal fluid findings, neurophysiology, and targeted serology. Early identification is critical, as delayed treatment risks life-threatening respiratory failure or autonomic instability. First-line therapies — intravenous immunoglobulin and plasmapheresis — remain standard, while newer targeted immunotherapies are emerging for distinct GBS variants. The review aims to equip clinicians with a current, practical framework for rapid diagnosis and individualized treatment.
Detailed Summary
Guillain-Barré syndrome represents a family of acute immune-mediated peripheral neuropathies and is the leading cause of acute flaccid paralysis in clinical practice globally. Understanding its variants, triggers, and treatment options is essential for neurologists and emergency physicians managing patients with rapidly progressing weakness.
This updated review from the Neuromuscular Pathology Unit at Hospital Sant Joan de Déu in Barcelona examines the full diagnostic and therapeutic landscape of GBS. The authors cover the most prevalent subtype — acute inflammatory demyelinating polyneuropathy (AIDP) — alongside axonal variants including AMAN (acute motor axonal neuropathy), AMSAN (acute motor-sensory axonal neuropathy), and the distinctive Miller-Fisher syndrome, which presents with ophthalmoplegia, ataxia, and areflexia.
Diagnosis remains primarily clinical, supported by cerebrospinal fluid analysis (notably albuminocytologic dissociation), neurophysiological studies distinguishing demyelinating from axonal injury, and specific ganglioside antibody serology in select variants. The authors stress that early recognition is paramount, as GBS can rapidly progress to respiratory failure and severe dysautonomia — both potentially fatal without prompt intervention.
Therapeutically, intravenous immunoglobulin (IVIg) and plasma exchange remain the established first-line treatments. Notably, the review highlights emerging targeted immunotherapies showing promise for specific GBS variants, reflecting a shift toward precision medicine approaches in neuroimmunology.
As this is a review article based solely on the abstract, specific data, patient numbers, and strength of evidence for individual recommendations cannot be fully evaluated. Nonetheless, the work provides a timely, clinically oriented synthesis that is especially relevant for pediatric and adult neurologists navigating the heterogeneous presentations of GBS.
Key Findings
- GBS is the leading cause of acute flaccid paralysis; AIDP is its most common subtype.
- Axonal variants (AMAN, AMSAN) and Miller-Fisher syndrome require distinct diagnostic recognition.
- Diagnosis combines clinical findings, CSF analysis, neurophysiology, and ganglioside serology.
- Early detection prevents fatal complications including respiratory failure and severe dysautonomia.
- Targeted immunotherapies are emerging as treatment options for specific GBS variants.
Methodology
This is a narrative review article published in a Spanish-language supplement, drawing on existing literature to summarize diagnostic and therapeutic approaches to GBS. Only the abstract is available, limiting detailed assessment of the evidence base and selection criteria used. The authors represent a specialized pediatric neuromuscular unit, suggesting a likely emphasis on pediatric presentations.
Study Limitations
Only the abstract was available, preventing evaluation of the specific evidence grades or references supporting treatment recommendations. As a review rather than original research, no new clinical data or patient outcomes are reported. The article is published in Spanish, which may limit accessibility for non-Spanish-speaking clinicians.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: